Union Health Ministry Classifies Pregabalin as Schedule H1 to Mitigate Misuse Concerns

The Union Health Ministry announced a decision aimed at addressing concerns surrounding the misuse and abuse of Pregabalin, especially among the youth. This action follows reports from various states indicating an increase in the improper use of the medication.

Pregabalin, primarily prescribed for conditions such as neuropathic pain and epilepsy, has come under scrutiny due to its potential for dependence and misuse. The ministrys decision underscores the importance of monitoring the distribution and consumption of pharmaceuticals to ensure public health safety.

Further details about the specific measures to be implemented, such as potential restrictions or guidelines for prescribing practices, have not yet been disclosed. The ministry is expected to collaborate with health authorities and stakeholders to develop strategies that mitigate abuse while still allowing access for patients who genuinely need this medication for legitimate medical reasons.